An observational study in Critical Illness, Dysphagia and Intensive Care Unit Acquired Weakness, sponsored by University of Rostock. Terminated at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-12.
Sponsored by University of Rostock · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Deglutition Disorders with a site in Germany — 6 open to participants now, 6 under way, none of them phase 3. Deglutition Disorders · Germany.
Among the 27 studies in Deglutition Disorders with a site in Germany, this one is the only one that started in 2020, is one of 9 observational ones, and was the 20th registered.
875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.
Browse Deglutition Disorders studies →6 of the 27 studies in Deglutition Disorders with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Muenster · Sites in Germany
Ages 18+
Heinrich-Heine University, Duesseldorf · Sites in Germany
Ages 18+
University of Giessen · Sites in Germany
Ages 18–100
Kliniken Beelitz GmbH · Sites in Germany
Ages 18+
University of Giessen · Sites in Germany
Ages 18+ · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 137 Deglutition Disorders studies recruiting now, 75 (55%) set no upper age limit and 26 (19%) stop at 75 or younger; 15 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2020.
This study's enrollment of 5 is below the median of 91 across 250 observational studies indexed under Deglutition Disorders.
Median enrollment 60 across the 18 interventional studies, 350 across the 9 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 27 have an industry lead sponsor. The 10 most frequent:
University of Rostock is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
University of Rostock has 2 studies filed under Deglutition Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies in Deglutition Disorders with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299448Heinrich-Heine University, DuesseldorfBiological Determinants and Neural Compensation of Dysphagia in Parkinson's Disease | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Deglutition Disorders with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dysphagia and the intensive care unit-acquired weakness (ICU-AW) are common and outcome-relevant neuromuscular complications in critically ill patients, especially after prolonged mechanical ventilation, sepsis and multi-organ failure. However, the impact of these two complications on the clinical course of critically ill patients needs further investigation.
Furthermore, the standard diagnostic procedure to detect and grade the acquired dysphagia using the fiberoptic endoscopic evaluation of swallowing (FEES) and the Medical Research Council sum score (MRC-ss) to detect ICU-AW are time-consuming and strongly dependent on patient compliance. An early and easy-to-use detection of these neuromuscular complications is currently difficult to be achieved in this patient population.
Neuromuscular ultrasound (NMUS) and the measurement of neuromuscular damage blood biomarkers became increasingly interesting for clinical researchers in the recent years due to their broad availability and their simple and non-invasive application. However, the value of these new diagnostic tests to evaluate dysphagia and ICU-AW needs to be verified.
In this single-center observational study the investigators aim to evaluate neuromuscular ultrasound and blood biomarkers of neuromuscular damage as innovative diagnostic features for the detection, monitoring and prognostication of dysphagia and ICU-AW in critically ill patients. A detailed neurological examination, NMUS as well as blood biomarker measurements (e.g. Myl3, TNNI1, FABP-3) will be longitudinally performed at study day 1 (day of study inclusion), day 3, day 10 and day 17 after study inclusion. The neurological examination comprises the use of validated scales (GCS, RASS, mRS) and scores (MRC-ss) to assess consciousness, neurological disability and muscle strength as well as the the examination of the reflex status. Using a standardized in-house NMUS protocol the facial (masseter muscle), submental (digastricus muscle, mylohyoid muscle), cervical (sternocleidomastoid muscle) and extremity muscles (biceps brachii, brachiradialis, quadriceps femoris, tibialis anterior) as well as the vagus nerve will be assessed repeatedly. Additionally, a FEES as the current gold standard diagnostic for dysphagia will be performed at study day 10 or as soon as possible (depending on the ability of the patient to cooperate with the examiner) after study day 10 to detect and grade the dysphagia.
All study participants will be reevaluated at day 90 after study inclusion with regard to functional disability and survival.
Furthermore, healthy volunteers will be recruited and assessed in the same way as patients including a clinical examination, NMUS, laboratory testing and FEES.
The investigators hypothezise that:
875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.
This study's enrollment of 5 is below the median of 91 across 250 observational studies indexed under Deglutition Disorders.
Browse Deglutition Disorders studies →University of Rostock is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
Compared within Deglutition Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
All patients admitted to the intensive care units of the study center will be screened for study eligibility according to the inclusion and exclusion criteria. Additionally, healthy volunteers will be recruited to participate as controls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* critically ill patients more than 17 years of age * matching study inclusion criteria * confirmed newly acquired swallowing dysfunction using FEES at study day 10 or later * ICU-AW positive (MRC-ss \<48) or ICU-AW negative (MRC-ss ≥48)
* critically ill patients more than 17 years of age * matching study inclusion criteria * newly acquired swallowing dysfunction ruled out using FEES at study day 10 or later * ICU-AW positive (MRC-ss \<48) or ICU-AW negative (MRC-ss ≥48)
* healthy volunteers without any neuromuscular disease * swallowing dysfunction ruled out using FEES
Incidence of sensomotory dysphagia in critically ill patients with and without intensive care unit-acquired weakness as well as controls
Assessment of dysphagia and ICU-AW using validated diagnostics (FEES, NMUS) and scores (MRC-ss)
Time frame: Day 90
Changes in ultrasonographic parameters between patients with and without newly acquired sensomotory dysphagia as well as controls
NMUS protocol performed at study days 1, 3, 10 and 17
Time frame: Change from baseline ultrasound parameters at day 17
Change in neuromuscular damage blood biomarker levels in critically ill patients with and without newly acquired sensomotory dysphagia as well as controls
Specific blood biomarker levels (e.g. TNNI1, FABP-3) measured at study days 1, 3, 10 and 17
Time frame: Change from baseline parameters at day 17
Quality of life in patients with and without neuromuscular complications after hospital discharge
Assessment of the overall quality of life using validated tests \[e.g. Modified Rankin Scale with a range from 0 (no symptoms) to 6 (dead)\]
Time frame: Day 90
Length of hospital stay comparing critically ill patients with and without neuromuscular complications
Cumulative days in hospital
Time frame: 1 year
Survival in critically ill patients with and without neuromuscular complications
Survival after 28 days
Time frame: Day 28
Survival in critically ill patients with and without neuromuscular complications
Survival after 90 days
Time frame: Day 90
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2020 to primary completion in Dec 2024, 51 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Rostock